We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Saliva Test More Accurately Indicates Severity of Recurrent Respiratory Infections in Children

By LabMedica International staff writers
Posted on 09 Aug 2024
Print article
Image: Non-invasive saliva testing aids in diagnosis and treatment of recurrent respiratory infections in children (Photo courtesy of Radboudumc)
Image: Non-invasive saliva testing aids in diagnosis and treatment of recurrent respiratory infections in children (Photo courtesy of Radboudumc)

Approximately 10-15% of children experience recurrent respiratory infections, prompting hospital visits where blood tests are commonly performed to check for antibody deficiencies. Yet, these tests often fail to provide helpful insights. There is a pressing need for alternative methods that better assess the severity of the condition, which would aid in determining when increased care or antibiotic treatment is necessary. Now, new research reveals that saliva testing might offer a more accurate reflection of the severity of recurrent respiratory infections in children compared to traditional blood tests. If saliva contains too few broadly protective antibodies, there is a higher likelihood of pneumonia episodes for the children.

The collaborative study by researchers at Radboudumc Amalia Children's Hospital (Nijmegen, Netherlands) and UMC Utrecht Wilhelmina Children's Hospital (Utrecht, Netherlands) involving 100 children with recurrent respiratory infections found that saliva tests are better indicators of disease severity than blood tests. The study demonstrated no significant correlation between blood antibodies and the extent of infection. However, saliva revealed the presence of broadly protective antibodies effective against various pathogens. Children with lower levels of these antibodies in their saliva experienced more severe infections. Interestingly, these antibodies are common in the airways of healthy individuals, including siblings and parents of affected children and their caregivers. A high level of these antibodies in saliva correlates with a strong defense against respiratory infections. Remarkably, these antibodies were even capable of binding to the SARS-CoV-2 virus in samples collected before the pandemic. Despite their abundance in saliva, these antibodies are rarely detected in blood.

The research also explored the balance of healthy and potentially harmful bacteria within the airway's mucous membranes, or microbiome. It identified a specific bacterium, Haemophilus influenzae, on the nasopharyngeal mucosa that is closely linked to the severity of respiratory infections. While this bacterium is also found in healthy airways, its high abundance is associated with increased illness frequency during the winter months, and it has been previously associated with pneumonia episodes. The findings, published in the European Respiratory Journal, highlight the potential of saliva and nasopharyngeal mucosal measurements as valuable tools in evaluating children with recurrent respiratory infections. Saliva testing not only offers new avenues for treatment but also sheds light on preventive measures; for instance, the flu vaccine has been shown to boost the level of protective antibodies in the saliva of healthy caregivers. Further research is underway to explore the potential of these antibodies in treating respiratory infections more effectively in the future.

“This helps us assess the amount of care and medication children need and which antibiotic to use, as the current standard does not work optimally against Haemophilus influenzae,” said PhD student Mischa Koenen. “I expect the initial blood test to remain, but for follow-up appointments, a more child-friendly saliva and nasopharyngeal swab could be used as indicators of expected respiratory disease burden.”

Related Links:
Radboudumc Amalia Children's Hospital
UMC Utrecht Wilhelmina Children's Hospital

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.